Sanofi Buys Blueprint Medicines for $9.1 Billion

Sanofi has announced its acquisition of US-based Blueprint Medicines for approximately $9.1 billion in cash, with the total deal value potentially reaching $9.5 billion if certain clinical and regulatory milestones are met. The transaction, the largest European pharma deal of 2025, involves a $129 per share cash payment, reflecting a 27% premium over Blueprint's recent closing price. Through the deal, Sanofi acquires Blueprint’s FDA-approved Ayvakit, currently the only treatment for advanced systemic mastocytosis, and access to its early-stage immunology pipeline. This move strengthens Sanofi's portfolio in immunology and rare diseases and aligns with its strategic focus on the US market and innovation. Industry analysts predict strong future sales for Ayvakit and see the acquisition as reinforcing Sanofi’s commitment to R&D. The deal follows Sanofi's recent strategic investments and setbacks, including the failure of a phase 3 study for a smoker’s bronchitis drug.